Conba Subsidiary Acquires Greater China Rights to Innovative Pain Drug Cebranopadol with $17.5 Million Upfront Payment

Corporate Action
โดย Jiemian·Read original
Summary · why it matters

Conba's wholly owned subsidiaries Hangzhou Conba and Hong Kong Conba have signed an agreement with Adneuris Therapeutics to acquire exclusive development and commercialization rights to cebranopadol in Greater China. Cebranopadol is a first-in-class oral analgesic targeting both NOP and MOP receptors, has completed Phase III clinical trials, and is expected to submit a new drug application to the US FDA this year. Conba will pay an upfront fee of $17.5 million, up to $94 million in milestone payments, and tiered royalties.

Impact on stocks 1

Others▲ · 1 stocks

Off-coverage companies 1

Adneuris TherapeuticsPrivate▲ Positive
Capitalrelevance

Adneuris receives $17.5M upfront and potential milestones from licensing deal.

© 2026 MarketDXNews